


FIGURE 1



CD146
65.8%
STRO-4 (HSP-90β)
87.8%
CD14
0.1%
CD34
0.1%
STRO-1
36.0%
CD45
0.5%
Fluorescence Intensity
Relative Cell Number

FIGURE 2



Day #
-7
5
1
3
7
28
48
50
51
63
70
71
72
81
83
88
HDM sensitisation and challenge
Aerosol challenges with HDM
Monitoring
Clinical monitoring
Weight measurement
Clinical Pathology
Blood*
BAL
Lung Function
BHR
Lung function (EAR & LAR)
Treatment (MPCs or saline)
Group Allocation
IV injection of test article
Sacrifice
Sacrifice
* Blood collected for haematology, biochemistry, cytokines and IgE assay.

Figure 3



(A) Early phase asthmatic response (EAR)
Change in resistance (%)
400
300
200
100
0
**
pre treatment
1wk post treatment
4wk post treatment
Control group
25million cMPC
75million cMPC
150million cMPC
(B)
Percentage change in EAR
1 week post treatment compared with pre treatment
1 week vs pretreatment (% change)
100
50
0
-50
-100
-150
Control group
25million cMPC
75million cMPC
150million cMPC
(C)
Percentage change in EAR
4 weeks post treatment compared with pre treatment
*
4 week vs pretreatment (% change)
100
50
0
-50
-100
-150
control group
25million cMPC
75million cMPC
150million cMPC

Figure 4



(A) Late phase asthmatic response (LAR), 6 hours
Change in resistance (%)
200
150
100
50
0
**
Pre treatment
1wk post treatment
4wk post treatment
Control group
25million dMPC
75million dMPC
150million dMPC
(B)
Percentage change in 6hr LAR
1 week post treatment compared with pre treatment
1 week vs pretreatment (% change)
50
0
-50
-100
*
Control group
25million dMPC
75million dMPC
150million dMPC
(C)
Percentage change in 6hr LAR
4 weeks post treatment compared with pre treatment
4 week vs pretreatment (% change)
50
0
-50
-100
Control group
25million dMPC
75million dMPC
150million dMPC

Figure 5



(A) Bronchial hyperresponsiveness (BHR)
Pre treatment
1wk post treatment
4wk post treatment
Breath units of carbachol
Control group
(B)
Percentage change in BHR
(C)
Percentage change in BHR
(D)
Bronchial hyperresponsiveness (BHR)
Control
Treated
pre treatment
1wk post treatment
4wk post treatment

Figure 6



(A) Percentage of eosinophils in BAL fluid
(B) Eosinophils/mL of BAL fluid
Pre treatment
1wk post treatment
4wk post treatment
(C)
(D)
(E)

Figure 7




Figure 8




Figure 9



(A) Percentage lymphocytes in BAL fluid
(B) Lymphocytes/ml. BAL fluid
Pre treatment
1wk post treatment
4wk post treatment

Figure 10



(A) IgE ELISA Absorbance in Serum
Absorbance
1.5
1.0
0.5
0.0
Pre-treatment
1wk post treatment
4wk post treatment
*
**
*
Control
25million oMPC
75million oMPC
150million oMPC
(B) Percentage change in IgE absorbance
1 week post treatment compared with pre treatment
1 week vs pretreatment (% change)
40
20
0
-20
-40
-60
Control group
25million oMPC
75million oMPC
150million oMPC
(C) Percentage change in IgE absorbance
4 weeks post treatment compared with pre treatment
4 week vs pretreatment (% change)
40
20
0
-20
-40
-60
Control group
25million oMPC
75million oMPC
150million oMPC

Figure 11